Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
USPIO-MRI for infiltrative glioblastoma extent
2023-000068-80Phase 2Active
- Sponsor
- Radboud University Medical Center
- Start
- Feb 2023
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of iron polymaltose in glioblastoma (GBM) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Feasibility of USPIO-MRI in healthy controls and glioblastoma patients. Started Feb 2023; status: active.
02
Drugs
iron polymaltose
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2023-000068-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-000068-80.